Navigation Links
Pressure BioSciences, Inc. Issued First Patent in Canada
Date:8/30/2007

WEST BRIDGEWATER, Mass., Aug. 30 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that it has been issued its first patent by the Canadian Intellectual Property Office. Entitled "Pressure-Mediated Binding of Biomolecular Complexes" (Number 2,259,318), this issuance extends the coverage of the Company's pressure cycling technology (PCT) patents previously issued in the United States, Japan, Germany, Italy, France, Sweden, Switzerland, and the U.K. The PCT methods covered by this patent relate to the association and disassociation of biomolecular complexes (such as antigen/antibody complexes) and the separation of biomolecules (such as proteins) from complex mixtures. Such methods may better enable the separation and purification of biomolecules (procedures that are performed routinely in pharmaceutical, biotechnology, and research laboratories) and may also improve the speed and sensitivity of both research and diagnostic tests, such as those used worldwide in the cancer, endocrine, and infectious diseases areas.

Richard T. Schumacher, Founder, President, and CEO of PBI said: "We continue to focus our primary PCT efforts in the potentially large and rewarding area of sample preparation. We concomitantly look to add value by reviewing our extensive patent portfolio outside of sample preparation to determine if our PCT intellectual property may help others improve their efforts in the therapeutic, diagnostics, or research areas."

Schumacher continued: "The PCT methods covered by this patent have the potential to play a significant role in improving the speed, ease-of-use, and sensitivity of both diagnostic and research tests currently used in laboratories today. The addition of Canada to the list of countries in which patents with similar claims have already been issued adds measurably to the value of this exciting PCT application."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential of the Company's PCT in sample preparation and for other applications, the protection that issued patents may provide, and the size of the commercial markets for PCT applications. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the risk that the Company's products will not achieve market acceptance in the area of sample preparation or in other applications; the risk that the Company's issued patents, including the newly issued Canadian patent, may not prevent competitors from developing and selling competitive technology; the risk that, due to the technological developments of others, the Company may be unable to continue to extend its patent protection; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.

Edward H. Myles, Senior Vice President

of Finance & CFO (508) 580-1818 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Analysis of Polycyclic Aromatic Hydrocarbons (PAHs) by LC/MS/MS Using an Atmospheric Pressure Photoionization Source
2. Determination of N-nitrosamines in Baby Bottle Rubber Teats by Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass Spectrometry
3. Screening of Corticosteroids in Urine by Negative Atmospheric Pressure Chemical Ionization LC/MS/MS
4. Medical College receives $11 million grant to study high blood pressure
5. Pressure mounts for Doyle to repeal shareholder liability law
6. Probe into gas gouging may educate Americans about pressures on oil supply
7. SWIB gets more pressure to invest in state tech start-ups
8. Technology puts pressure on old education methods
9. The Genesis of Gendicine: The Story Behind the First Gene Therapy
10. Midwest life science stocks sizzle in a tepid first quarter
11. Morgridge Institute for Research seeks first CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) ... portfolio of bioprocess media products engineered to radically streamline culture processes, minimize ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/7/2016)... ... 2016 , ... ACEA Biosciences, Inc. presented today updated efficacy ... for its lead drug candidate, AC0010, at the World Conference on Lung Cancer ... the safety, antitumor activity, and recommended phase II dosage of AC0010 in T790M-postitive ...
(Date:12/7/2016)... Capital Corp. ("Zenith" or the "Company") announces webcast details for ... Annual and Special Meeting. The Zenith Annual ... December 15, 2016 at Mount Royal ... Royal Gate SW, Calgary, Alberta , commencing ... information circular, containing the matters to be considered at the ...
Breaking Biology Technology:
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... announces that it has just released a new white paper authored by Zettar that ... speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
Breaking Biology News(10 mins):